All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the unique challenges to CMV prophylaxis in patients with acute or chronic GvHD?

During the 2021 ASCO Annual Meeting, the GvHD Hub spoke with Delaney Wolfe, The Ohio State University, Columbus, US. We asked, What are the unique challenges to cytomegalovirus (CMV) prophylaxis in patients with acute or chronic GvHD?

What are the unique challenges to CMV prophylaxis in patients with acute or chronic GvHD?

Wolfe evaluates the use of letermovir for CMV prophylaxis. This includes the need for long-term data that observes treatment past day 100 post-allo-HCT, the challenges for CMV monitoring in patients who progress to chronic GvHD, and whether the benefits of letermovir outweigh its costs.

Share:
More about...

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox